FDA Announces Availability of All Doses of Novo Nordisk’s Ozempic and Wegovy

Availability Update:
The FDA has updated its drug shortages database to indicate that all doses of Novo Nordisk's semaglutide, sold as Ozempic for type 2 diabetes and Wegovy for obesity, are now available.

Supply Management:
Novo Nordisk has been managing shipments of the 0.25 mg starting dose of Wegovy to ensure continuity of care for existing patients while increasing production capacity.

Production Efforts:
Novo Nordisk has made significant investments in manufacturing, including a $6 billion boost to its production capacity in Denmark and a $4.1 billion commitment to its North Carolina facility.

Regulatory Status:
Despite the availability of all doses, the FDA still lists semaglutide as "currently in shortage" due to ongoing supply and demand dynamics.

Compounding Concerns:
The FDA's update raises questions about whether compounders will need to stop producing and marketing remixed versions of semaglutide, and whether the FDA will enforce action against these pharmacies.

Market Impact:
The availability of all doses is a positive development for Novo Nordisk, which has struggled to meet demand for these blockbuster GLP-1 drugs.